Rituximab® and high dose methylprednisolone (HDMP) for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.

被引：0
|
作者：
Castro, JE
Bole, J
Prada, CE
Kipps, TJ
机构：
[1] Univ Calif San Diego, John & Rebecca Moores Canc Ctr, La Jolla, CA 92093 USA
[2] Chron Lymphocyt Leukemia Res Consortium, CRC, San Diego, CA USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2518
引用
收藏
页码：690A / 690A
页数：1
相关论文
共 50 条
  • [41] Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia
    Robak, Tadeusz
    Smolewski, Piotr
    Cebula, Barbara
    Grzybowska-Izydorczyk, Olga
    Blonski, Jerzy Z.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) : 107 - 113
  • [42] Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
    Coutre, Steven E.
    Flinn, Ian W.
    de Vos, Sven
    Barrientos, Jacqueline C.
    Schreeder, Marshall T.
    Wagner-Johnson, Nina D.
    Sharman, Jeff P.
    Boyd, Thomas E.
    Fowler, Nathan
    Dreiling, Lyndah
    Kim, Yeonhee
    Mitra, Siddhartha
    Rai, Kanti
    Leonard, John P.
    Furman, Richard R.
    HEMASPHERE, 2018, 2 (03):
  • [43] DOSE DENSE HIGH DOSE METHYLPREDNISOLONE (HDMP) AND RITUXIMAB (RTX) ARE EFFECTIVE IN RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION (17P DEL) / TP53 MUTATION
    Pileckyte, R.
    Valceckiene, V.
    Zvirblis, T.
    Griskevicius, L.
    HAEMATOLOGICA, 2012, 97 : 525 - 526
  • [44] Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
    Wierda, W
    O'Brien, S
    Wen, S
    Faderl, S
    Garcia-Manero, G
    Thomas, D
    Do, KA
    Cortes, J
    Koller, C
    Beran, M
    Ferrajoli, A
    Giles, F
    Lerner, S
    Albitar, M
    Kantarjian, H
    Keating, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (18) : 4070 - 4078
  • [45] UPDATED RESULTS OF A PHASE II STUDY OF LENALIDOMIDE AND RITUXIMAB IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA.
    Piris-Villaespesa, M.
    Chavez, J.
    Dalia, S.
    Veliz, M.
    Lancet, Jeffrey
    Bello, C.
    Turba, E.
    Shah, B.
    Komrokji, R.
    Sokol, L.
    Locke, F.
    Kharfan-Dabaja, M.
    Sotomayor, E.
    Pinilla-Ibarz, J.
    HAEMATOLOGICA, 2013, 98 : 46 - 46
  • [46] Obinutuzumab (Gazyva) and High-Dose Methylprednisolone (HDMP) Combination for Patients with Chronic Lymphocytic Leukemia (CLL) - a Phase Ib/II Study
    Castro, Januario E.
    Amaya-Chanaga, Carlos I.
    Lujan, Juliana Velez
    Choi, Michael
    McCarthy, Colin
    Kipps, Thomas J.
    BLOOD, 2017, 130
  • [47] Acalabrutinib in Combination With Venetoclax and Obinutuzumab or Rituximab in Patients With Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 9 - 10
  • [48] Acalabrutinib in Combination with Venetoclax and Obinutuzumab or Rituximab in Patients with Treatment-Naive or Relapsed/Refractory Chronic Lymphocytic Leukemia
    Woyach, Jennifer A.
    Blachly, James S.
    Rogers, Kerry A.
    Bhat, Seema A.
    Grever, Michael R.
    Kittai, Adam S.
    Jianfar, Mojgan
    Lozanski, Gerard
    Weiss, David M.
    Andersen, Barbara L.
    Patel, Priti
    Munugalavadla, Veerendra
    Butturini, Anna
    Xu, Yan
    Wang, Min Hui
    Byrd, John C.
    BLOOD, 2020, 136
  • [49] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    Shustik, C.
    Bence-Bruckler, I.
    Delage, R.
    Owen, C. J.
    Toze, C. L.
    Coutre, S.
    ANNALS OF HEMATOLOGY, 2017, 96 (07) : 1185 - 1196
  • [50] Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
    C. Shustik
    I. Bence-Bruckler
    R. Delage
    C. J. Owen
    C. L. Toze
    S. Coutre
    Annals of Hematology, 2017, 96 : 1185 - 1196
12345